Loading organizations...
Just - Evotec Biologics is a contract development and manufacturing organization (CDMO) based in Seattle, Washington, specializing in the AI-driven design, development, and manufacturing of protein therapeutics. The company leverages innovative platforms like J.DESIGN to advance partner molecules from discovery through clinical stages to commercial launch for the biopharmaceutical industry. Initially operating with approximately 90 employees, the firm was acquired by Evotec SE in 2019 for $90 million, subsequently becoming a wholly owned subsidiary. Prior to its acquisition, Just Biotherapeutics garnered support from notable entities including ARCH Venture Partners, Merck, LAV, and the Bill & Melinda Gates Foundation. It was founded in 2014 as Just Biotherapeutics by a team of former Amgen scientists. Its business model centers on operates as a CDMO providing services to biotech and pharma partners, wholly owned subsidiary of Evotec SE.
Just - Evotec Biologics has raised $86.0M across 3 funding rounds.
Just - Evotec Biologics has raised $86.0M in total across 3 funding rounds.
Just - Evotec Biologics has raised $86.0M in total across 3 funding rounds.
Just - Evotec Biologics's investors include Temasek, ARCH Venture Partners, Bank of China, Bank of Hangzhou, East China Internet Industry Park, Lilly Asia Ventures, Taikang, Bill & Melinda Gates Foundation, Merck.
Just - Evotec Biologics has raised $86.0M across 3 funding rounds. Most recently, it raised $57.0M Series B in August 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 8, 2017 | $57M Series B | Temasek | ARCH Venture Partners, Bank OF China, Bank OF Hangzhou, East China Internet Industry Park, Lilly Asia Ventures, Taikang | Announced |
| Jul 25, 2016 | $14M Series A | Bill & Melinda Gates Foundation | ARCH Venture Partners, Lilly Asia Ventures, Merck | Announced |
| Sep 21, 2015 | $15M Series A | — | ARCH Venture Partners, Lilly Asia Ventures, Merck | Announced |
